National Cancer Survivors Day

National Cancer Survivors Day

July 29, 2008

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 17 No 7

Volume 17

Issue 7

CHICAGO-Sunday, June 1 marked the 15th annual Cancer Survivors’ Celebration and Walk, sponsored by the Robert H. Lurie Cancer Center of Northwestern University as part of National Cancer Survivors Day. More than 800 cancer survivors participated in the walk (see photograph).

Articles in this issue

National Cancer Survivors Day

New Indication for Velcade in Previously Untreated Myeloma

Risk Factors for Mantle Cell Lymphoma Identified

RAS Mutations Enhance Chemotherapy in AML

Antidiabetic Agent Metformin May Boost pCRs in Breast Ca

Eisai Seeks Full FDA Approval for Ontak for CTCL

Symptom Screen Plus CA125 Detects Early Ovarian Ca

Cisplatin Linked to Cardiac Complications in Testicular Ca Patients

Updated X-ACT Study Results Presented

ThromboGenics and BioInvent Announce Alliance with Roche

Gene Signature Identifies Low-Risk Patients in MAGE-A3 Trial

p110-Beta Drives Cancer Growth When PTEN is Inhibited, Animal Study Shows

Proton beam RT not exempt from evidence-based medicine

Investigational Agents May be Effective for Resistant GIST

Coverage vs Cost-Cutting: A look Inside the Obama and McCain Healthcare Plans

Related Content

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024

Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024

Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024

Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024

Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024

Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.